Corcept Therapeutics Incorporated (BIT:1CORT)

Italy flag Italy · Delayed Price · Currency is EUR
68.94
+0.64 (0.94%)
At close: May 28, 2025
8.81%
Market Cap 6.48B
Revenue (ttm) 634.17M
Net Income (ttm) 122.60M
Shares Out n/a
EPS (ttm) 1.06
PE Ratio 52.86
Forward PE 41.96
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open n/a
Previous Close 68.30
Day's Range n/a
52-Week Range 62.20 - 68.94
Beta n/a
RSI 38.32
Earnings Date Jul 30, 2025

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 500
Stock Exchange Borsa Italiana
Ticker Symbol 1CORT
Full Company Profile

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD Financial Statements

News

There is no news available yet.